Literature DB >> 12788309

Modulation of pro- and anti-inflammatory cytokine production in very preterm infants.

Joerg Dembinski1, Daniela Behrendt, Rainer Martini, A Heep, Peter Bartmann.   

Abstract

BACKGROUND: In premature infants, outcome of infection-associated complications is heterogeneous despite advances in antibiotic treatment and diagnosis. Information on the immune response in preterm infants is limited. Immune modulatory strategies require detailed analysis of mediators and their kinetics.
OBJECTIVE: To determine the kinetics of IL-1beta, TNFalpha, IL-6, IL-8, IL-10, gammaINF and G-CSF in preterm and term infants in an ex vivo cord blood culture (CBC) endotoxin model. DESIGN AND METHODS: Cord blood of 25 infants was obtained immediately after birth from the fetal side of the placenta and incubated in culture medium (RPMI 1640) in the presence or absence of 500 pg/ml lipopolysaccharide (LPS) for 48h. TNFalpha, IL-1beta, IL-6 and IL-8 were measured by sequential immunometric assay (IMMULITE, DPC Biermann, Germany); IL-10 (Milenia Biotec, Bad Nauheim, Germany), gammaINF (Diaclone, Besancon, France) and G-CSF (R & D Systems, Wiesbaden, Germany) were determined by ELISA in supernatants at 0, 4, 8, 12, 24 and 48h. Infants were stratified into three gestational age groups (< or =32 weeks, 33-36 weeks, > or =37 weeks). Variations between the groups were first analyzed for significance by Kruskal-Wallis test and pairs were compared by Mann-Whitney-U test. Effects of gestational age, leucocyte count, hematocrit and frequency of antenatal steroid exposure were tested by linear regression analysis. To correct a possible impact of variable, WBC count, cytokine levels were adjusted according to individual leucocyte numbers.
RESULTS: LPS-stimulated maximum levels of IL-6, IL-1beta,TNFalpha and G-CSF in CBC were significantly lower in very preterm infants compared to more advanced gestational age groups. After adjusting the cytokine levels for 10(5) leucocytes, a significant effect of gestational age on IL-6 and G-CSF production (p<0.05) was detected. A non-significant trend towards reduced cytokine levels was observed following multiple antenatal steroid exposures. IL-10:TNFalpha ratio increased in very preterm neonates when compared with the advanced gestational age, although the increase was not significant.
CONCLUSIONS: Pro-inflammatory cytokine activity in CBC correlates with gestational age, whereas IL-10 does not. Although ex vivo synthesis of IL-1beta, TNFalpha, IL-6, G-CSF in CBC depends in part on leucocyte numbers, IL-6 and G-CSF synthesis appeared to be related to immaturity. Non-significant effects of multiple antenatal steroid exposure and increased IL-10:TNFalpha ratio in preterm neonates, observed in a small sample size, warrant further investigation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12788309     DOI: 10.1016/s1043-4666(02)00498-2

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  25 in total

1.  Association of interferon gamma T+874A and interleukin 12 p40 promoter CTCTAA/GC polymorphism with the need for respiratory support and perinatal complications in low birthweight neonates.

Authors:  G Bokodi; L Derzbach; I Bányász; T Tulassay; B Vásárhelyi
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2006-06-05       Impact factor: 5.747

2.  Profound lack of interleukin (IL)-12/IL-23p40 in neonates born early in gestation is associated with an increased risk of sepsis.

Authors:  Pascal M Lavoie; Qing Huang; Elyse Jolette; Mihoko Whalen; Anne Monique Nuyt; Francois Audibert; David P Speert; Thierry Lacaze-Masmonteil; Hugo Soudeyns; Tobias R Kollmann
Journal:  J Infect Dis       Date:  2010-10-26       Impact factor: 5.226

3.  Maturation of CD4+ regulatory T lymphocytes and of cytokine secretions in infants born prematurely.

Authors:  V Dirix; F Vermeulen; F Mascart
Journal:  J Clin Immunol       Date:  2013-06-21       Impact factor: 8.317

4.  NICU admission hypothermia, chorioamnionitis, and cytokines.

Authors:  Karen D Fairchild; Chen-Chih J Sun; George C Gross; Adora C Okogbule-Wonodi; Rose M Chasm; Rose M Viscardi
Journal:  J Perinat Med       Date:  2011-08-13       Impact factor: 1.901

5.  A three-dimensional mathematical and computational model of necrotizing enterocolitis.

Authors:  Jared Barber; Mark Tronzo; C Harold Horvat; Gilles Clermont; Jeffrey Upperman; Yoram Vodovotz; Ivan Yotov
Journal:  J Theor Biol       Date:  2012-12-07       Impact factor: 2.691

6.  Association of antenatal steroid use with cord blood immune biomarkers in preterm births.

Authors:  Praveen Kumar; Scott A Venners; Lingling Fu; Colleen Pearson; Katherin Ortiz; Xiaobin Wang
Journal:  Early Hum Dev       Date:  2011-05-14       Impact factor: 2.079

Review 7.  Mechanisms linking preterm birth to onset of cardiovascular disease later in adulthood.

Authors:  Mahesh Bavineni; Trudy M Wassenaar; Kanishk Agnihotri; David W Ussery; Thomas F Lüscher; Jawahar L Mehta
Journal:  Eur Heart J       Date:  2019-04-07       Impact factor: 29.983

8.  Preterm infants have deficient monocyte and lymphocyte cytokine responses to group B streptococcus.

Authors:  Andrew J Currie; Samantha Curtis; Tobias Strunk; Karen Riley; Khemanganee Liyanage; Susan Prescott; Dorota Doherty; Karen Simmer; Peter Richmond; David Burgner
Journal:  Infect Immun       Date:  2011-02-07       Impact factor: 3.441

9.  Parental characteristics, somatic fetal growth, and season of birth influence innate and adaptive cord blood cytokine responses.

Authors:  Diane R Gold; Gordon R Bloomberg; William W Cruikshank; Cynthia M Visness; John Schwarz; Meyer Kattan; George T O'Connor; Robert A Wood; Melissa S Burger; Rosalind J Wright; Frank Witter; Aviva Lee-Parritz; Rhoda Sperling; Yoel Sadovsky; Alkis Togias; James E Gern
Journal:  J Allergy Clin Immunol       Date:  2009-11       Impact factor: 10.793

Review 10.  The developing human preterm neonatal immune system: a case for more research in this area.

Authors:  Ashish Arunkumar Sharma; Roger Jen; Alison Butler; Pascal M Lavoie
Journal:  Clin Immunol       Date:  2012-08-17       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.